Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the study is to determine the factors affecting the bioavailability of iron and folic acid during the simultaneous use of iron supplements and folic acid supplements in non-pregnant women of childbearing age.
Scientists in the field of nutrition and gynecology and obstetrics have been paying attention to the need of use iron and folate supplements in women of childbearing age. Increased intake of micronutrients in the diet or the use of supplementation does not always bring the expected results, what depends on factors that affect the bioavailability of minerals and vitamins. On the one hand these factors are related to the properties of food intake, e.g. to the presence of other nutrients that can increase or decrease the absorption of folates and iron (eg vitamin C, phytates), and on the other hand the functioning of the body itself, which to a certain extent is determined by genetic factors (e.g., genetically determined reduced activity of methylenetetrahydrofolate reductase [MTHFR], which reduces the bioavailability of folic acid).
The study aims:
assessment of the effect of simultaneous supplementation with iron and folate on:
the estimation of gene polymorphisms encoding proteins transporting iron and folate
obtaining information whether the polymorphism of genes encoding proteins transporting iron and folate is related to the effectiveness of the iron and folic acid supplementation used in non-pregnant women of childbearing age.
In 200 non-pregnant women of childbearing age a blood level of iron and folic acid will be determined. Subjects with low level of blood iron and folic acid will be supplemented with oral iron and folic acid for 3 months. Subjects with proper level of blood iron and folic acid will be a control group. At baseline and at completion of the study (after 3 months) fasting blood will be collected and abovementioned parameters will be estimated.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Folic acid and iron supplementation | Experimental | Individuals with low level of blood folic acid and iron- will receive folic acid and iron supplementation daily, for 3 months |
|
| Control group | Active Comparator | Individuals with proper level of blood folic acid and iron- will not receive folic acid and iron supplementation daily, for 3 months |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Folic acid and iron supplementation | Dietary Supplement | Individuals with low level of blood folic acid and iron- will receive folic acid and iron supplementation daily, for 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| folic acid concentrations at baseline | blood folic acid concentrations at baseline | At the baseline |
| folic acid concentrations after 3 months of treatment | blood folic acid concentrations after 3 months of treatment | after 3 months of treatment |
| iron concentrations at baseline | blood iron concentrations at baseline | At the baseline |
| iron concentrations after 3 months of treatment | blood ron concentrations after 3 months of treatment | after 3 months of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| blood pressure | blood pressure | At the baseline |
| body mass | body mass | At the baseline |
Not provided
Inclusion Criteria:
Exclusion Criteria:
female gender based on self-representation
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Joanna Suliburska, Ass Prof | Institute of Human Nutrition and Dietetics, Poznań University of Life Sciences | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Poznan University of Life Sciences | Poznan | 60-624 | Poland |
Not provided
| ID | Term |
|---|---|
| D009748 | Nutrition Disorders |
| ID | Term |
|---|---|
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D005492 | Folic Acid |
| D035061 | Control Groups |
| ID | Term |
|---|---|
| D011622 | Pterins |
| D011621 | Pteridines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Control group | Dietary Supplement | Individuals with proper level of blood folic acid and iron- will not receive folic acid and iron supplementation daily, for 3 months |
|
| body height | body height | At the baseline |
| Body % fat | Fat tissue % estimated with air displacement plethysmography | At the baseline |
| Body % muscle | Muscle tissue % estimated with BodPod (air displacement plethysmography) | At the baseline |
| ferritin at the baseline | serum ferritin concentration at the baseline | At the baseline |
| ferritin after 3 months of treatment | serum ferritin concentration after 3 months of treatment | after 3 months of treatment |
| hepcidin at the baseline | serum hepcidin concentration at the baseline | At the baseline |
| hepcidin after 3 months of treatment | serum hepcidin concentration after 3 months of treatment | after 3 months of treatment |
| homocysteine at the baseline | serum homocysteine concentration at the baseline | At the baseline |
| homocysteine after 3 months of treatment | serum homocysteine concentration after 3 months of treatment | after 3 months of treatment |
| total iron-binding capacity (TIBC) at the baseline | Blood total iron-binding capacity at the baseline | At the baseline |
| TIBC after 3 months of treatment | Blood total iron-binding capacity after 3 months of treatment | after 3 months of treatment |
| divalent metal transporter 1 (DMT1) gene polymorphisms | polymorphisms of gene encoding divalent metal transporter 1 | At the baseline |
| transferrin receptor 2 (TfR2) gene polymorphisms | polymorphisms of gene encoding transferrin receptor 2 | At the baseline |
| proton-coupled folate transporter (PCFT) gene polymorphisms | polymorphisms of gene encoding proton-coupled folate transporter | At the baseline |
| reduced folate carrier (RFC) gene polymorphisms | polymorphisms of gene encoding reduced folate carrier | At the baseline |
| D006571 | Heterocyclic Compounds |
| D015340 | Epidemiologic Research Design |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D012107 | Research Design |
| D008722 | Methods |